Renovacor, a preclinical stage gene therapy company developing a pipeline of AAV-based gene therapies, went public via a SPAC merger with Chardan Healthcare, a SPAC, in a $95m deal. "We believe Renovacor’s sound development strategy, experienced management team and world-class scientific advisors will position the company for sustained success. We expect the added financial flexibility provided by its public listing and concurrent financing will accelerate the development of Renovacor’s pipeline to create much needed therapies for patients, while potentially generating significant long-term value for stockholders," Jonas Grossman, President and CEO.